More articles from Research Watch

MYC Interacts with the G9a Methyltransferase to Repress Target Genes
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-179
IRE1α–XBP1 Suppresses the Antitumor Activity of T Cells
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-182
RUNX1–ETO Upregulates CCND2 to Drive Leukemogenesis
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-180
Inhibiting C5a Enhances Chemotherapeutic Efficacy
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-181
Neoadjuvant Immune Checkpoint Blockade Has Antitumor Activity
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-178
Mevalonate Pathway Inhibitors May Be Effective Cancer Vaccine Adjuvants
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-175
c-KIT Has a Tumor-Suppressive Role via Induction of Apoptosis
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-177
Antibody-Dependent Cellular Cytotoxicity Renders Macrophages Immunosuppressive
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-176
Oncogenic Epithelial Reprogramming Drives Neuroendocrine Cancers
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-173
Telisotuzumab Vedotin Has Activity in Patients with MET-Positive NSCLC
Cancer Discovery Oct 2018, DOI: 10.1158/2159-8290.CD-RW2018-174

Main menu